Related Experiment Video
Updated: Aug 14, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Interferon gamma treatment for cervical intraepithelial neoplasia
T Iwasaka1, Y Hayashi, M Yokoyama
1Department of Obstetrics and Gynecology, Saga Medical School, Japan.
Insights
Human recombinant interferon gamma (IFN-gamma) injections effectively treated cervical intraepithelial neoplasia (CIN) in eight patients. IFN-gamma demonstrated potential in differentiating cells and improving CIN lesions, showing promising therapeutic effects.
Area of Science:
- Gynecology
- Oncology
- Immunology
Background:
- Cervical intraepithelial neoplasia (CIN) is a precancerous condition of the cervix.
- Current treatments for CIN can be invasive and may have side effects.
- Interferon-gamma (IFN-gamma) is a cytokine with known immunomodulatory and anti-proliferative properties.
Purpose of the Study:
- To evaluate the efficacy of human recombinant interferon gamma (IFN-gamma) in treating cervical intraepithelial neoplasia (CIN).
- To assess the potential of IFN-gamma to induce cellular differentiation in CIN lesions.
Main Methods:
- Eight patients with CIN received perilesional injections of human recombinant IFN-gamma.
- Treatment response was monitored using colposcopy, exfoliative cytology, and histopathology.
- A control group of eight patients was observed for spontaneous regression.
Main Results:
- All patients showed improvement in colposcopic and cytologic findings after IFN-gamma treatment.
- Cytologic findings normalized in five patients, who were free of dysplastic lesions.
- Histopathology confirmed residual dysplasia in three patients who underwent hysterectomy or laser conization.
- Only one patient in the control group showed spontaneous regression.
- IFN-gamma treatment was associated with the presence of keratinizing cells, suggesting differentiation.
Conclusions:
- Human recombinant IFN-gamma is an effective therapeutic agent for CIN lesions.
- IFN-gamma may induce differentiation of nonkeratinizing squamous cells into keratinizing cells.
- IFN-gamma offers a potential new treatment modality for cervical intraepithelial neoplasia.
Abstract:
Eight patients with cervical intraepithelial neoplasia (CIN) were administered perilesional injections of human recombinant interferon gamma (IFN-gamma), and the response was evaluated by colposcopy and exfoliative cytology and then by histopathology. In all patients, colposcopic and cytologic findings improved after two to four injections of IFN-gamma and the cytologic findings reverted to normal in five of these eight patients. All five were free of dysplastic lesions. The other three patients with positive cytology and positive colposcopy after completion of IFN-gamma treatment underwent hysterectomy or laser conization, and histopathologic examination revealed residual dysplastic lesions. On the other hand, a control study revealed that only one of eight patients showed spontaneous regression during the 3-month observation period. During the course of these treatments, keratinizing cells were often present in the cervical smears and isolated cell keratinization was often evident in the residual dysplastic lesions of the surgical specimens. These observations suggest that IFN-gamma treatment is an effective therapeutic method for CIN lesions and that IFN-gamma has the potential to differentiate nonkeratinizing squamous cells into keratinizing cells.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Inhibitors of Viral Protein Synthesis
01:22Antiviral Nucleoside Inhibitors